{"filing":{"accession_number":"0001746473-26-000107","cik":"0001746473","ticker":"PLRX","company_name":"PLIANT THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"plrx-20260709.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647326000107/plrx-20260709.htm"},"events":[{"id":17612,"run_id":15780,"accession_number":"0001746473-26-000107","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of two new directors—Robert Iannone, M.D., M.S.C.E. as a Class I director and Flavia Borellini, Ph.D. as a Class II director—to fill newly-created board vacancies following an increase in authorized board size from seven to nine members. Dr. Borellini was also appointed chairperson of the R\u0026D Committee. This is a clear executive appointment event material to investors assessing board composition and governance.","company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":16155,"accession_number":"0001746473-26-000107","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two new directors—Robert Iannone, M.D., M.S.C.E. as a Class I director and Flavia Borellini, Ph.D. as a Class II director—to fill newly-created board vacancies following an increase in authorized board size from seven to nine members. Dr. Borellini was also appointed chairperson of the R\u0026D Committee. This is a clear executive appointment event material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:26:36.278731+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16155,"accession_number":"0001746473-26-000107","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of two new directors—Robert Iannone, M.D., M.S.C.E. as a Class I director and Flavia Borellini, Ph.D. as a Class II director—to fill newly-created board vacancies following an increase in authorized board size from seven to nine members. Dr. Borellini was also appointed chairperson of the R\u0026D Committee. This is a clear executive appointment event material to investors assessing board composition and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T20:26:36.278731+00:00","company_name":"PLIANT THERAPEUTICS, INC.","ticker":"PLRX","filing_date":"2026-07-13"}]}